Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emmaus Life SciencesEMMA 3-Year EBITDA Growth Rate is 64.40% as of Mar. 2026, which is 132% above its 10-year median of 27.80. The stock has 6 warning signs investors should review. Among 1,135 Biotechnology companies, Emmaus Life Sciences ranks better than 91.54% on this metric.
During the past 12 months, Emmaus Life Sciences's average EBITDA Per Share Growth Rate was -185.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 64.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Emmaus Life Sciences was 79.60% per year. The lowest was -622.50% per year. And the median was 27.80% per year.
Emmaus Life Sciences (OTCPK:EMMA) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Emmaus Life Sciences 3-Year EBITDA Growth Rate Related Terms
EMMA vs AGTX, BZYR, ATXI: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's 3-Year EBITDA Growth Rate falls into.
Emmaus Life Sciences 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 64.40% mean?
Emmaus Life Sciences (EMMA) has a 3-Year EBITDA Growth Rate of 64.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Emmaus Life Sciences and its competitors. This is 132% above median its historical median of 27.80. According to the industry distribution chart, Emmaus Life Sciences ranks #96 out of 1135 companies in the Biotechnology industry, placing it in the top 8.5%.
Is Emmaus Life Sciences' 3-Year EBITDA Growth Rate too high?
Emmaus Life Sciences' current 3-Year EBITDA Growth Rate of 64.40% is 132% above median its 10-year median of 27.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Emmaus Life Sciences' value of 64.40% is 332.2% above this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #96 out of 1135 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Emmaus Life Sciences' 3-Year EBITDA Growth Rate compare to AGTX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #96 out of 1135 companies for 3-Year EBITDA Growth Rate. This places Emmaus Life Sciences in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Emmaus Life Sciences' value of 64.40% is 332.2% above this benchmark. While the company's 10-year median is 27.80 vs. the industry median of 14.90, Emmaus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current 3-Year EBITDA Growth Rate of 64.40% is 332.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current 3-Year EBITDA Growth Rate is 64.40%, which is 132% above median its own 10-year median of 27.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current 3-Year EBITDA Growth Rate is 64.40%, which is 132% above median its 10-year median of 27.80 and 332.2% above the Biotechnology industry median of 14.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current 3-Year EBITDA Growth Rate is 64.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 
